Blackstone Announces $4.6 Billion Final Close of Life Sciences Fund

Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V (BXLS V), the inaugural Blackstone fund in Life Sciences.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, July 9, 2020
Information
Tags: 
Professional services, Health, Finance, General Health, Pharmaceutical, Banking, Biotechnology, Private equity firms, Finance, Blackstone, Alternative investment management companies, The Blackstone Group, Private equity in the 2000s
Geotags: 
United States, NEW YORK
⚠ generated by AI ↴
Organisation: 
BLACKSTONE LIFE SCIENCES
Summary
Key Points: 
  • Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V (BXLS V), the inaugural Blackstone fund in Life Sciences.
  • BXLS V was oversubscribed and closed at its hard cap of $4.6 billion of total capital commitments the largest life sciences private fund raised to date.
  • Blackstone Life Sciences has three main investment strategies: strategic collaborations with established life science companies, late-stage product financings, and growth investments in emerging companies.
  • Over the past three months, Blackstone Life Sciences invested capital from BXLS V in the following transactions:
    In April, Blackstone Life Sciences entered into a $2 billion strategic collaboration with Alnylam , a leading biotechnology company, the largest private financing of a pre-profitability stage biotechnology company.


Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V (“BXLS V”), the inaugural Blackstone fund in Life Sciences. BXLS V was oversubscribed and closed at its hard cap of $4.6 billion of total capital commitments —the largest life sciences private fund raised to date.

Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences, said, “Our mission to bring innovative medicines to patients by drawing on our domain expertise and scale capital has resonated with investors. With many more promising products in the life sciences industry’s pipeline than capital available to advance them, we look forward to continuing to bring new treatment options and innovations to the patients who need them.”

Blackstone Life Sciences has three main investment strategies: strategic collaborations with established life science companies, late-stage product financings, and growth investments in emerging companies.

Over the past three months, Blackstone Life Sciences invested capital from BXLS V in the following transactions:

  • In April, Blackstone Life Sciences entered into a $2 billion strategic collaboration with Alnylam, a leading biotechnology company, the largest private financing of a pre-profitability stage biotechnology company. A key element of this investment was the acquisition of a royalty interest in inclisiran, a Novartis-owned LDL lowering medicine that has the potential to transform the lives of patients with heart disease.
  • In June, Blackstone Life Sciences led a $350 million investment in Reata Pharmaceuticals to help advance the first potential medicine for Alport Syndrome, a kidney disease that afflicts children.
  • Also in June, Blackstone Life Sciences and Medtronic announced a $337 million strategic collaboration to advance Medtronic‘s next generation of diabetes management products. This was the first investment by Blackstone Life Sciences in the medical devices space.

About Blackstone Life Sciences

Blackstone Life Sciences is a private, global investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines that improve patients’ lives.

Copyright: 
Copyright Business Wire 2020